These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 22423577)

  • 1. Relationship among changes in hematocrit, albumin and corticosteroid dose on the disposition of tacrolimus during the first six months following renal transplantation.
    Robles-Piedras AL; Romano-Moreno S; Fuentes-Noriega I; Mancilla-Urrea E; González-López EH; Domínguez-Ramírez A
    Proc West Pharmacol Soc; 2011; 54():30-2. PubMed ID: 22423577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients.
    Staatz CE; Willis C; Taylor PJ; Tett SE
    Clin Pharmacol Ther; 2002 Dec; 72(6):660-9. PubMed ID: 12496747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
    Kuypers DR; Vanrenterghem Y
    Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
    Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
    Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation.
    Budde K; Fritsche L; Mai I; Bauer S; Smettan S; Waiser J; Hofmann T; Hauser I; Reinke P; Neumayer HH
    Int J Clin Pharmacol Ther; 1996 Nov; 34(11):493-7. PubMed ID: 8937932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients.
    Minematsu T; Sugiyama E; Kusama M; Hori S; Yamada Y; Ohtani H; Sawada Y; Sato H; Takayama T; Sugawara Y; Makuuchi M; Iga T
    Transplant Proc; 2004 Jun; 36(5):1506-11. PubMed ID: 15251372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus trough levels and level-to-dose ratio in stable renal transplant patients converted to a once-daily regimen.
    Meçule A; Tinti F; Poli L; Bachetoni A; Umbro I; Nofroni I; Lai Q; Pretagostini R; Berloco PB; Mitterhofer AP
    Transplant Proc; 2011 May; 43(4):1024-7. PubMed ID: 21620042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients.
    Lumlertgul D; Noppakun K; Rojanasthien N; Kanchanarattanakorn K; Jittikanont S; Manoyot A; Bunnachak D; Ophascharoensuk V
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S73-8. PubMed ID: 17044457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients.
    Zhang XQ; Wang ZW; Fan JW; Li YP; Jiao Z; Gao JW; Peng ZH; Liu GL
    Ther Drug Monit; 2012 Apr; 34(2):126-33. PubMed ID: 22377746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation.
    Staatz CE; Taylor PJ; Lynch SV; Tett SE
    Liver Transpl; 2004 Apr; 10(4):506-12. PubMed ID: 15048793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different evolution of trough and dose levels during the first year after transplantation for tacrolimus versus cyclosporine.
    Lemahieu WP; Maes BD; Vanrenterghem Y
    Transplant Proc; 2005 Jun; 37(5):2051-3. PubMed ID: 15964336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients.
    Yeung S; Tsang WK; Tong KL; Wong SH; Lee W; Tang HL; Chan HW; Chan AY
    Transplant Proc; 2004 Sep; 36(7):2084-6. PubMed ID: 15518754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus clearance is age-dependent within the pediatric population.
    Przepiorka D; Blamble D; Hilsenbeck S; Danielson M; Krance R; Chan KW
    Bone Marrow Transplant; 2000 Sep; 26(6):601-5. PubMed ID: 11041564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circadian and time-dependent variability in tacrolimus pharmacokinetics.
    Park SI; Felipe CR; Pinheiro-Machado PG; Garcia R; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2007 Apr; 21(2):191-7. PubMed ID: 17391292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period.
    Blanchet B; Duvoux C; Costentin CE; Barrault C; Ghaleh B; Salvat A; Jouault H; Astier A; Tod M; Hulin A
    Ther Drug Monit; 2008 Aug; 30(4):412-8. PubMed ID: 18641556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression.
    Wagner K; Webber SA; Kurland G; Boyle GJ; Miller SA; Cipriani L; Griffith BP; Fricker FJ
    J Heart Lung Transplant; 1997 Mar; 16(3):275-82. PubMed ID: 9087870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion to tacrolimus extended-release formulation: short-term clinical results.
    Gallego-Valcarce E; Ortega-Cerrato A; Llamas-Fuentes F; Martinez-Fernandez G; Perez-Martinez J; Gomez-Roldan C
    Transplant Proc; 2009; 41(6):2326-7. PubMed ID: 19715909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients.
    Min DI; Chen HY; Lee MK; Ashton K; Martin MF
    Pharmacotherapy; 1997; 17(3):457-63. PubMed ID: 9165550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.